Novo Nordisk halts Wegovy sales on Hims & Hers, claiming “deceptive marketing” practices

Novo Nordisk has terminated its partnership with Hims & Hers Health due to allegations of the telehealth company selling counterfeit versions of its weight-loss drug, Wegovy, which posed safety risks to patients. This decision follows a recent collaboration intended to enhance accessibility to obesity treatments, with Hims & Hers shares dropping by approximately 31% after the announcement.

Need More Context? 🔎